Management Team

Steven W. King

President and CEO, Director

Steve King was appointed President and CEO of Peregrine Pharmaceuticals in March 2003 and has led the company into three Phase II clinical programs.  Mr. King joined the company in 1997 as Director of R&D.  In 2000, Steve was responsible for bringing the company’s biomanufacturing facility into full cGMP compliance and then launching Peregrine’s subsidiary Avid Bioservices. Prior to joining Peregrine, Steve worked with a company that was developing Vascular Targeting Agents and with UT Southwestern Medical Center with the inventor of Peregrine’s technology.  Steve holds BS and MS degrees in Biology from Texas Tech University.

 

Paul J. Lytle

Chief Financial Officer

Paul J. Lytle has served as Chief Financial Officer since August 2002 and has over 17 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a B.S. in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.

 

Joseph S. Shan, M.P.H.

Vice President, Clinical & Regulatory Affairs

Joseph S. Shan has served as Vice President, Clinical & Regulatory Affairs since March 2009 and previously served as our head of Clinical and Regulatory Affairs since January 2003. He is responsible for the design and execution of our clinical trials and overseeing regulatory submissions. Since joining Peregrine in 2000, Mr. Shan has been instrumental in advancing the clinical development of the Company's bavituximab and Cotara ® antibody products. Prior to joining Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter Healthcare Corporation) and Sulzer Medica. Mr. Shan received his B.S. degree in Physiological Sciences from the University of California, Los Angeles and his M.P.H. degree from the George Washington University in Washington, D.C. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals and the Regulatory Affairs Professionals Society.

 

Shelley P. M. Fussey, Ph.D.

Vice President, Intellectual Property

Shelley P.M. Fussey, Ph.D. has served as our Vice President, Intellectual Property since February 2005. Dr. Fussey plays a key role in our U.S. and international patenting, patent analysis and patent defense. Dr. Fussey's expertise includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development. Prior to joining Peregrine, Dr. Fussey worked for the law firms of Williams, Morgan & Amerson and Arnold, White and Durkee. She holds a Ph.D. in Biochemistry and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University of Newcastle upon Tyne, U.K.

 

Mark R. Ziebell, Esq.

Vice President, General Counsel and Corporate Secretary

Mark Ziebell was appointed Vice President and General Counsel of Peregrine Pharmaceuticals in June 2012.  Prior to joining Peregrine, Mark was a Partner at Snell & Wilmer LLP, a law firm based in Orange County, California where his practice specialized in securities law, mergers and acquisitions, corporate governance and general corporate law representing companies in a broad range of industries including the biopharmaceutical and technology sectors. In that role, Mark represented Peregrine since 1999 serving as an advisor to both management and the board of directors. Prior to Snell & Wilmer he was a Partner at the law firm of Falk, Shaff & Ziebell where he was part of the Corporate and Securities practice area. Prior to that Mark has held positions of increasing responsibility within the accounting and legal sectors. Mark holds a JD degree from the University of San Francisco, School of Law and a BA in Accounting from the University of San Francisco.

 

Jeff T. Hutchins, Ph.D.

Vice President, Preclinical Research

Dr. Hutchins was appointed Vice President of Preclinical Research in September 2012. Prior to joining Peregrine,  Jeff served for the last 5 of 11 years as Vice President, Pre-clinical Development at Inhibitex Inc, which was recently acquired by Bristol-Myers Squibb. From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College. Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at Houston’s Graduate School of Biomedical Sciences at the M.D. Anderson Hospital and Cancer Center and conducted postdoctoral training in the University of Southern California’s Department of Microbiology at the Norris Cancer Center. Dr. Hutchins’ publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology.

 

Stephen T. Worsley

Vice President, Business Development

Stephen Worsley was appointed vice president of business development in November 2013 bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Prior to joining Peregrine he was chief business officer at Centrose Pharmaceuticals and prior to that he held the position of vice president of business development at Intrexon Inc., Zosano Pharma Inc., (a spin out of Johnson & Johnson) and Raven Biotechnologies, Inc. (acquired by MacroGenics).  In addition, he was director of business development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen holds an MBA in finance from the University of Washington and a Bachelor of Science in international economics and finance from the University of Utah.

 

Robert L. Garnick, Ph.D.

Head of Regulatory Affairs

Dr. Garnick has over 30 years of experience in drug and biologic pharmaceutical development. He was formerly the Senior Vice President of Regulatory, Quality and Compliance at Genentech, Inc. Dr. Garnick spent 24 years at Genentech helping to found the biotechnology industry. While at Genentech Dr. Garnick was responsible for the approval of over 17 drugs, biologics and medical devices. He has extensive experience in analytical methodology, process validation, the regulatory review process both in the US and Europe and in Risk assessments. He has authored numerous scientific papers and has given numerous keynote presentations to the pharmaceutical Industry.

 

Kerstin B. Menander, M.D., Ph.D.

Head of Medical Oncology

Kerstin Menander, M.D., Ph.D. has been Peregrine’s Head of Medical Oncology since March 2011. She supports the planning and execution of Peregrine’s numerous clinical trials for oncology indications. Dr. Menander has 30 years of experience in drug development, having held senior positions in Abbott Laboratories, Syntex Laboratories, Introgen Therapeutics, Collagen Corporation, and Cell Pathways. At these companies, she led the clinical and regulatory strategy and development of drugs, biologics, and devices. She has led the international management of various clinical trials, which have supported 15 approvals for various indications in the U.S. and Europe including Lupron®, the leading therapy for the treatment of prostate cancer. Her regulatory experience includes leading the successful development of several INDs, IDEs, NDAs, BLAs (also accelerated), PMAs and conditional and regular MMAs. Dr. Menander earned her medical degree and Ph.D. in Histology from the University of Lund in Sweden.

 

Mary J. Boyd, Ph.D.

Head of Business Development for Asia and Europe

Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. Dr. Boyd was previously director, Asia, worldwide business development, R&D for GlaxoSmithKline; head of business development and licensing in Japan for Novartis; and head, licensing and patent group for Roche in Japan. In these positions, she identified new opportunities, negotiated global agreements and maintained productive relationships with other companies. Dr. Boyd holds a Ph.D. in Developmental Genetics from the University of Cambridge, UK and a B.Sc. in Biochemistry from the University of Sussex, UK.